Dose-dense chemotherapy for early breast cancer found safe, similar to standard regimen

December 06, 2005

Biweekly chemotherapy treatment--a dose-dense regimen--for patients with early-stage breast cancer was found to be as safe as treatment administered every third week; however, the dose-dense regimen did not result in improvements in recurrence or survival, according to a study in the December 7 issue of the Journal of the National Cancer Institute.

In standard adjuvant therapy for breast cancer, chemotherapy is administered every 3 weeks. However, scientists have been testing whether more frequent administration of chemotherapy would more effectively kill rapidly dividing cancer cells. In 2003, the Cancer and Leukemia Group B reported results of their randomized clinical trial of dose-dense chemotherapy, which found that a dose-dense regimen improved disease-free and overall survival in lymph node-positive early-stage breast cancer.

The Italian clinical trials group Gruppo Oncologico Nord Ovest-Mammella InterGruppo (GONO-MIG) launched a randomized clinical trial to determine whether dose-dense treatment increased overall survival and prevented relapse and whether more frequent treatment was safe or increased the level of toxic effects such as anemia, bone pain, white blood cell count, and weakness. A total of 1214 women with early-stage breast cancer were randomly assigned to receive six courses of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) either every 2 weeks (dose-dense regimen) or every 3 weeks (standard regimen). Women on the dose-dense regimen were also given filgrastim, a drug that stimulates the production of white blood cells.

Marco Venturini, M.D., of the National Cancer Research Institute in Genoa, Italy, and colleagues report that, after a median follow-up of 10.4 years, the dose-dense regimen was associated with a 13% reduced risk of death; however, this reduction was not statistically significant. Women in the dose-dense group experienced higher rates of acute toxic effects from anemia, thrombocytopenia, and bone pain. However, the authors note that these toxic effects were mild and easy to manage.

The study had some limitations. The authors designed the study to determine if the dose-dense regimen could reduce the risk of death by 32% or more. In addition, patient enrollment into the clinical trial was stopped early because of problems recruiting patients to the study.

"[O]ur results support the long-term safety of the ... dose-dense chemotherapy regimen with filgrastim support as an adjuvant treatment for breast cancer," the authors write. "The dose-dense strategy was not statistically significantly associated with improved outcome, but, because of the limited statistical power of our study and the trend for an improved outcome observed, we cannot rule out the possibility of a modestly improved outcome."

"Overall, the study was thoughtfully designed, and the results are mature," write Eric P. Winer, M.D., and colleagues at the Dana-Farber Cancer Institute in Boston. Winer and colleagues write that, despite non-statistically significant results, there is still "solid evidence, in the context of other trial data, that using a dose-dense approach can decrease the risk of disease recurrence and improve overall survival."
-end-
Contacts:
  • Article: Gianni Vasino, National Cancer Research Institute, Genoa, Italy, Gianni.Vasino@istge.it, 39 010 5600 091
  • Editorial: Bill Schaller, Dana-Farber Cancer Institute, 617-632-5357, William_Schaller@dfci.harvard.edu

    Citations:
  • Article: Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, et al. Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results from a Randomized Trial. J Natl Cancer Inst 2005;97:1724-1733.
  • Editorial: Lin NU, Gelman R, Winer EP. Dose Density in Breast Cancer: A Simple Message? J Natl Cancer Inst 2005;97:1712-1714.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

    Journal of the National Cancer Institute

    Related Breast Cancer Articles from Brightsurf:

    Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
    The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

    Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
    New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

    Partial breast irradiation effective treatment option for low-risk breast cancer
    Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

    Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
    Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

    More clues revealed in link between normal breast changes and invasive breast cancer
    A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

    Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
    A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

    Computers equal radiologists in assessing breast density and associated breast cancer risk
    Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

    Blood test can effectively rule out breast cancer, regardless of breast density
    A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

    Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
    Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

    Young breast cancer patients undergoing breast conserving surgery see improved prognosis
    A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

    Read More: Breast Cancer News and Breast Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.